
Ventas Financial Ratios 2025-2011 | VTR
Brief overview of Ventas's multiples and efficiency
Ratios are assessed across five available annual reports in the 2019–2025 interval.
The valuation comparison uses P/E 143.37x (median 143.37x), EV/EBITDA 27.77x (median 17.8x), P/S 6.43x (median 5.26x). Multiples are on average 22.3% above their own medians. A substantial share of positive expectations may already be priced in.
Current earnings relative to valuation equal about 0.7% on the 1/P/E measure. This is a valuation reference, not an expected payout.
Capital efficiency is characterized by ROE 2.1%, ROA 0.9%, ROCE 3.7%. Low capital returns limit the ability to compound value internally.
The cash cycle lengthened by 167.9 days to 6.5 days. Operations require more funding.
Overall picture
Ventas combines weak profitability with valuation above its historical norm, leaving limited cushion.
Annual Financial Ratios Ventas
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
143.4 | 300.7 | -583.9 | -494.3 | 355.7 | 37.4 | 49.0 | 55.6 | 14.3 | 32.6 | 43.7 | 56.4 | 45.6 | 61.3 | 41.6 |
P/S |
6.4 | 5.4 | 3.9 | 4.9 | 5.3 | 4.3 | 5.5 | 6.1 | 5.4 | 6.2 | 5.6 | 8.7 | 7.4 | 9.0 | 8.6 |
EPS |
0.6 | 0.2 | -0.1 | -0.1 | 0.1 | 1.2 | 1.2 | 1.1 | 3.8 | 1.9 | 1.3 | 1.6 | 1.6 | 1.2 | 1.6 |
EV (Enterprise Value) |
51.4 B | 40.7 B | 32 B | 33.7 B | 33.4 B | 29.4 B | 35.2 B | 35 B | 32.4 B | 33.5 B | 30.9 B | 39.2 B | 31.4 B | 32.1 B | 23 B |
EBITDA per Share |
3.03 | 3.04 | 3.47 | 3 | 3.13 | 2.97 | 5.15 | 5.27 | 5.48 | 5.44 | 5.29 | 5.91 | 5.38 | 4.81 | 5.16 |
EV/EBITDA |
27.8 | 18.9 | 17.6 | 17.8 | 15.7 | 17.1 | 16.8 | 21.7 | 19.0 | 21.6 | 18.3 | ||||
PEG |
171.51 | -39.74 | 105.39 | 52.43 | -42.11 | -4.17 | 18.77 | -0.8 | 0.14 | 0.66 | -1.97 | 12.48 | 1.82 | -2.72 | 21.75 |
P/B |
2.9 | 2.4 | 1.8 | 1.9 | 1.8 | 1.6 | 2.0 | 2.2 | 1.8 | 2.0 | 1.9 | 3.1 | 2.3 | 2.4 | 1.6 |
P/CF |
22.8 | 20.0 | 15.8 | 18.1 | 19.6 | 11.4 | 24.2 | 24.8 | 19.2 | 19.1 | 15.7 | 25.3 | 20.3 | 27.5 | 105.5 |
ROE % |
2.09 | 0.82 | -0.32 | -0.40 | 0.52 | 4.29 | 4.11 | 3.99 | 12.41 | 6.17 | 4.34 | 5.43 | 5.09 | 3.99 | 3.90 |
ROA % |
0.95 | 0.34 | -0.12 | -0.17 | 0.23 | 1.84 | 1.75 | 1.81 | 5.66 | 2.80 | 1.88 | 2.24 | 2.30 | 1.91 | 2.11 |
ROCE % |
- | - | - | - | - | - | 3.72 | 4.66 | 4.79 | 4.43 | 4.03 | 4.73 | 4.66 | 3.91 | 4.54 |
Current Ratio |
1.9 | 1.7 | 1.7 | 1.8 | 1.8 | 1.8 | 0.7 | 0.4 | 1.0 | 1.2 | 1.2 | 0.7 | 0.6 | 0.7 | 0.1 |
DSO |
6.5 | 6.8 | 3.1 | - | - | - | 99.0 | 73.0 | 165.6 | 100.1 | 116.7 | 113.4 | 68.5 | 111.0 | - |
DPO |
- | - | - | - | - | - | 231.0 | 234.4 | 290.4 | 229.8 | 201.7 | 302.7 | 327.0 | 370.9 | 583.9 |
Operating Cycle |
6.5 | 6.8 | 3.1 | - | - | - | 99.0 | 73.0 | 165.6 | 100.1 | 116.7 | 113.4 | 68.5 | 111.0 | - |
Cash Conversion Cycle |
6.5 | 6.8 | 3.1 | - | - | - | -132.0 | -161.4 | -124.7 | -129.7 | -85.0 | -189.2 | -258.5 | -260.0 | -583.9 |
All numbers in USD currency
Quarterly Financial Ratios Ventas
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.12 | - | 0.15 | 0.11 | - | 0.05 | 0.05 | -0.04 | - | -0.18 | 0.26 | 0.04 | - | - | -0.11 | 0.1 | - | 0.16 | 0.23 | -0.15 | 0.29 | 0.03 | -0.42 | 1.27 | 0.03 | 0.23 | 0.58 | 0.35 | 0.17 | 0.29 | 0.47 | 0.22 | 1.1 | 1.72 | 0.43 | 0.56 | 0.59 | 0.43 | 0.42 | 0.44 | 0.37 | 0.07 | 0.45 | 0.37 | 0.36 | 0.33 | 0.47 | 0.41 | 0.37 | 0.4 | 0.39 | 0.38 | 0.3 | 0.38 | 0.26 | 0.31 | 0.67 | 0.36 | 0.11 | 0.31 |
EBITDA per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | 0.75 | 0.71 | 0.72 | - | 0.82 | 0.67 | 0.84 | - | 0.67 | 0.94 | 0.67 | - | 0.63 | 0.63 | 0.66 | - | 0.61 | 0.63 | 0.65 | - | 0.6 | 0.63 | 0.61 | - | 0.59 | 0.65 | 0.7 | - | 0.68 | 0.65 | 0.66 | - | 0.59 | 0.65 | 0.66 | - | 0.6 | 0.59 | 0.6 | - | 0.64 | 0.65 | 0.56 | - | 1.76 | 0.45 | 0.32 |
ROE % |
2.11 | 1.25 | 1.47 | 1.07 | 0.30 | -0.40 | -1.32 | -0.49 | 0.53 | 0.56 | 1.29 | -0.14 | 0.02 | 0.58 | 1.11 | 2.39 | 0.90 | 2.00 | 1.57 | -0.89 | 4.33 | 3.36 | 4.05 | 7.65 | 4.21 | 4.70 | 4.88 | 4.51 | 4.07 | 7.08 | 18.59 | 29.46 | 41.20 | 39.57 | 33.28 | 26.98 | 20.68 | 19.99 | 18.14 | 16.30 | 14.45 | 14.38 | 15.50 | 16.61 | 17.73 | 17.72 | 17.38 | 17.04 | 16.69 | 16.42 | 15.28 | 14.13 | 12.99 | 14.11 | 11.21 | 7.41 | 3.93 | 1.11 | 0.21 | 0.53 |
ROA % |
0.94 | 0.54 | 0.62 | 0.44 | 0.12 | -0.16 | -0.52 | -0.19 | 0.22 | 0.23 | 0.52 | 0.27 | 0.34 | 0.59 | 0.66 | 1.04 | 0.39 | 0.86 | 0.67 | -0.38 | 1.84 | 1.43 | 1.72 | 3.25 | 1.78 | 2.01 | 2.11 | 2.00 | 1.84 | 3.21 | 8.43 | 13.36 | 18.69 | 17.95 | 15.08 | 12.21 | 9.34 | 9.00 | 8.07 | 7.14 | 6.21 | 6.16 | 6.53 | 6.89 | 7.26 | 7.30 | 7.35 | 7.41 | 7.47 | 7.37 | 6.97 | 6.57 | 6.17 | 6.84 | 5.52 | 3.73 | 2.11 | 0.60 | 0.11 | 0.28 |
ROCE % |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.77 | 7.55 | 7.55 | - | 3.77 | - | - |
Current Ratio |
2.0 | 1.9 | 1.8 | 1.8 | 1.7 | 1.7 | 1.7 | 1.6 | 1.7 | 1.7 | 1.7 | 1.8 | 1.8 | 1.8 | - | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 | 1.8 | 1.8 | 1.8 | 1.7 | 1.7 | 1.7 | 1.7 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 2.2 | 2.2 | 2.2 | 2.2 |
DSO |
5.7 | - | 5.1 | 6.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
5.7 | - | 5.1 | 6.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
5.7 | - | 5.1 | 6.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Ventas, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Reit healthcare industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Global Medical REIT
GMRE
|
- | - | $ 2.37 B | ||
|
Healthpeak Properties
PEAK
|
- | 2.09 % | $ 9.35 B | ||
|
The GEO Group
GEO
|
$ 30.92 | -0.48 % | $ 4.25 B | ||
|
National Health Investors
NHI
|
$ 80.54 | 0.74 % | $ 3.78 B | ||
|
LTC Properties
LTC
|
$ 42.18 | 0.98 % | $ 1.95 B | ||
|
Welltower
WELL
|
$ 252.07 | 2.03 % | $ 168 B | ||
|
Sabra Health Care REIT
SBRA
|
$ 22.36 | 1.5 % | $ 5.4 B | ||
|
Omega Healthcare Investors
OHI
|
$ 51.72 | 1.45 % | $ 15.1 B |